Open AccessClinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy
Author(s) -
Marco Gálvez,
Carlos A. Castañeda,
Joselyn Sanchez,
Miluska Castillo,
Lia P. Rebaza,
Gabriela Calderón,
Miguel De La Cruz,
José M. Cotrina,
Julio Abugattas,
Jorge Dunstan,
Henry Guerra,
Ómar Mejía,
Henry Gómez
Publication year - 2018
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v9.i2.33
Subject(s) - medicine , breast cancer , chemotherapy , tumor infiltrating lymphocytes , biopsy , population , stage (stratigraphy) , oncology , gastroenterology , pathological , pathology , h&e stain , neoadjuvant therapy , cancer , immunohistochemistry , immunotherapy , biology , paleontology , environmental health
To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC).